Question: Porcellini et al. investigated the effect on CD4 T cell count of administration of intermittent interleukin (IL-2) in addition to highly active antiretroviral therapy (HAART). The following table shows the CD4 T cell at baseline and then again after 12 months of HAART therapy with IL-2. Do the data show a significant change in CD4 T cell count at the .05 level of significance?